Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited)

v3.21.2
Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Income Statement [Abstract]        
Revenues, net $ 9,142,000 $ 3,623,000 $ 24,413,000 $ 5,511,000
Cost of revenues 4,676,000 2,344,000 11,020,000 3,817,000
Gross profit 4,466,000 1,279,000 13,393,000 1,694,000
Operating expenses:        
Diagnostic expenses 830,000 4,639,000
General and administration 4,993,000 1,155,000 8,775,000 2,323,000
Research and development 93,000 65,000 208,000 124,000
Total operating expenses 5,916,000 1,220,000 13,622,000 2,447,000
Income (loss) from operations (1,450,000) 59,000 (229,000) (753,000)
Interest income, net 214,000 11,000 301,000 14,000
Interest expense (323,000) (574,000)
Change in fair value of investment securities 164,000   164,000
Net income (loss) (1,395,000) 70,000 (338,000) (739,000)
Other comprehensive loss:        
Unrealized gain (loss) on marketable debt securities (67,000) (5,000) (78,000) 6,000
Total comprehensive income (loss) $ (1,462,000) $ 65,000 $ (416,000) $ (733,000)
Earnings (loss) per share:        
Basic $ (0.09) $ 0.01 $ (0.02) $ (0.06)
Diluted $ (0.09) $ 0.01 $ (0.02) $ (0.06)
Weighted average common shares outstanding:        
Basic 15,154 11,592 14,860 11,587
Diluted 15,154 11,618 14,860 11,587